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BrainCheck – a very brief tool to detect incipient
cognitive decline: optimized case-finding
combining patient- and informant-based data
Michael M Ehrensperger1*, Kirsten I Taylor1,2, Manfred Berres3, Nancy S Foldi4, Myriam Dellenbach5,6, Irene Bopp7,
Gabriel Gold8, Armin von Gunten9, Daniel Inglin10, René Müri11, Brigitte Rüegger7, Reto W Kressig12
and Andreas U Monsch1

Abstract
Introduction: Optimal identification of subtle cognitive impairment in the primary care setting requires a very brief
tool combining (a) patients’ subjective impairments, (b) cognitive testing, and (c) information from informants. The
present study developed a new, very quick and easily administered case-finding tool combining these assessments
(‘BrainCheck’) and tested the feasibility and validity of this instrument in two independent studies.
Methods: We developed a case-finding tool comprised of patient-directed (a) questions about memory and
depression and (b) clock drawing, and (c) the informant-directed 7-item version of the Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE). Feasibility study: 52 general practitioners rated the feasibility and
acceptance of the patient-directed tool. Validation study: An independent group of 288 Memory Clinic patients
(mean ± SD age = 76.6 ± 7.9, education = 12.0 ± 2.6; 53.8% female) with diagnoses of mild cognitive impairment
(n = 80), probable Alzheimer's disease (n = 185), or major depression (n = 23) and 126 demographically matched,
cognitively healthy volunteer participants (age = 75.2 ± 8.8, education = 12.5 ± 2.7; 40% female) partook. All
patient and healthy control participants were administered the patient-directed tool, and informants of 113
patient and 70 healthy control participants completed the very short IQCODE.
Results: Feasibility study: General practitioners rated the patient-directed tool as highly feasible and acceptable.
Validation study: A Classification and Regression Tree analysis generated an algorithm to categorize patient-directed
data which resulted in a correct classification rate (CCR) of 81.2% (sensitivity = 83.0%, specificity = 79.4%). Critically, the
CCR of the combined patient- and informant-directed instruments (BrainCheck) reached nearly 90% (that is 89.4%;
sensitivity = 97.4%, specificity = 81.6%).
Conclusion: A new and very brief instrument for general practitioners, ‘BrainCheck’, combined three sources of
information deemed critical for effective case-finding (that is, patients’ subject impairments, cognitive testing,
informant information) and resulted in a nearly 90% CCR. Thus, it provides a very efficient and valid tool to aid
general practitioners in deciding whether patients with suspected cognitive impairments should be further
evaluated or not (‘watchful waiting’).
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Introduction
Cognitive disorders are frequently underdiagnosed and,
consequently, diseases such as dementia are undertreated
[1]. The early identification of cognitive impairments is
critical to initiate diagnostic procedures, since early diagnoses lead to optimal treatment and potentially improve
prognoses and decrease morbidity. National task forces
and academies have concluded that routine dementia
screening – that is, population-based screening of individuals irrespective of the existence of cognitive complaints –
cannot be recommended based on existing data, most
notably screening tests’ mediocre diagnostic specificity
[2-5]. Instead, speciality groups recommend a case-finding
strategy whereby general practitioners (GPs) test patients
with suspected or observable early signs or symptoms of
cognitive impairment [6-10]. This strategy requires optimally sensitive and specific case-finding tools that are well
suited to the primary care setting.
Many patient-directed cognitive or informant-based
tools are available for case-finding in the primary care
setting [4,6,11-16]. Lin and colleagues list 51 such tools
in their comprehensive review [4]. Most were initially
designed as screening tools, and thus the majority were
evaluated in only one study relevant to the primary care
setting (that is, 36/51 instruments; see ‘supplements’ ,
‘supplemental content’, ‘supplement. additional information
on interventions’ in [4]). Of these tools, the best-studied
cognitive (patient-directed) case-finding tool is the MiniMental Status Examination (MMSE) [17]. However, the
MMSE suffers from low inter-rater reliability (IRR) and
low sensitivity for mild impairment (for example [18]) and
inappropriateness for primarily nonverbal forms of cognitive impairment (for example, mild cognitive impairment
(MCI) and dementia in Parkinson disease [19]). The
Montreal Cognitive Assessment is similar in design to
the MMSE in that it assesses multiple cognitive domains
and has a maximum of 30 points [20]. Compared with
the MMSE, the Montreal Cognitive Assessment identified more MCI and Alzheimer’s dementia (AD) patients
(sensitivity) but fewer healthy controls (specificity) [20].
Additional instruments include the Rowland Universal
Dementia Assessment Scale [21] and the CANTABmobile
(Cambridge Cognition, Cambridge, UK), a 10-minute to
15-minute screening instrument comprised of a visual
paired associates learning test, the Geriatric Depression
Scale, and assessment of activities of daily living. While
these tools are valuable instruments to quickly assess global cognitive functioning, particularly in a memory clinic
setting [22], their relatively long administration time and
potential burden to the patient–GP relationship reduce
their feasibility and acceptability in the primary care
setting.
Shorter patient-directed cognitive tools that have likewise
been well studied include the clock drawing test (CDT)
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[23], Mini-Cog [24], and the Memory Impairment Screen
[6,11-16,25]. The CDT primarily assesses executive
dysfunction and is less influenced by sociodemographic
factors (for example, educational level, language) than
other case-finding tools [14]. The CDT yields adequate
sensitivity and specificity for dementia when administered
on its own [14], which are improved when combined with
other cognitive instruments that assess episodic memory
functioning [26]. For example, the Mini-Cog combines the
CDT with a three-item delayed word recall task [24]. Also
the Mini-Cog can be administered very quickly (circa 3
minutes), has a high sensitivity and correct classification
rate (CCR), and is less susceptible to low education and
literacy than, for example, the MMSE [24,27]. The Memory Impairment Screen is a short cognitive case-finding
tool that focuses purely on episodic memory functioning
[25]. This four-item delayed and cued recall test can be
quickly administered and performance is not significantly
affected by demographic factors, but its sensitivity and
specificity are inferior to, for example, Mini-Cog [13].
Thus, short instruments that combine executive and
episodic memory assessments appear most promising
for accurate case-finding in the GP setting.
The subjective impression of the patient’s informant
(for example, family member) is a critical component of
an accurate assessment of the patient’s cognitive and
behavioral profiles [6,28,29], although this information
may not always be available. Informants may notice
changes in cognitive functioning not noticed by patients,
especially when patients suffer from neurodegenerative
syndromes associated with a lack of awareness [30]. One
widely used informant-directed tool that is available in
many different languages is the Informant Questionnaire
on Cognitive Decline in the Elderly (IQCODE) [31,32].
This tool performs adequately in the primary care setting
[4]. Moreover, a very short, seven-item version of the
IQCODE is available, which distinguishes healthy older
individuals from patients with AD and MCI with high
correct classification rates (that is, 90.5% and 80.1%,
respectively) [33]. The General Practitioner Assessment
of Cognition (GPCOG) [28] was developed specifically as
a GP case-finding tool and combines two critical sources
of information: patient-directed cognitive testing (that is
CDT, time orientation, a report of a recent event and a
word recall test) and informant-directed questioning (that
is, six informant questions asking whether the patient’s
functioning has changed compared with ‘a few years ago’).
Although the combination of two separate sources of
information is assumed to bolster diagnostic accuracy
compared with tests relying on one source of information,
surprisingly the diagnostic accuracy of the GPCOG was
comparable with that of the MMSE (that is, area under
the receiver operating characteristic curve = 0.91 vs. 0.89,
respectively) [28].
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Cordell and colleagues recently suggested that casefinding tools can be further optimized by including
questions on patient’s subjective functioning [6]. Indeed,
questions on subjective cognitive impairments [34] and
depression [35] are good predictors of the future development of, for example, MCI and dementia [36]. Moreover,
these questions are easy to administer in the primary care
setting as they typically correspond to the questions GPs
pose during routine history-taking.
The emerging consensus regarding case-finding for
patients with potential MCI and early dementia in the
primary care setting is that it optimally requires the
combination of patient-directed cognitive testing, informant information on patient functioning and patient information on subjective cognitive impairments [6]. However,
to our knowledge, no case-finding tool combines these
three components into a single tool that is feasible to
administer in the primary care setting; that is, a tool which
is very brief and nonthreatening. The first goal of this
study was therefore to develop a very brief, user-friendly
case-finding tool for primary care physicians that combines a patient-directed tool (that is, cognitive testing and
subjective patient information) and an informant-directed
tool (that is, subjective informant information). We then
performed a study to obtain GPs’ judgments on the
feasibility of the patient-directed instrument; that is, the
instrument administered by GPs. Finally, we conducted
a validation study to determine the optimal scoring criteria and corresponding CCR of the patient-directed
instrument alone (applicable in situations in which no
informant is available) and of the combined patientdirected and informant-directed tool; that is, BrainCheck.
The informant-directed instrument (that is, very short
IQCODE) was previously validated by Ehrensperger and
colleagues [33].
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Q1. Have you experienced a recent decline in your
ability to memorize new things?
Q2. Have any of your friends or relatives made remarks
about your worsened memory?
Q3. Do your memory or concentration problems affect
your everyday life?
Q4. During the past month, have you often been
bothered by feeling down, depressed or hopeless?
Q5. During the past month, have you often been bothered
by little interest or pleasure in doing things?
The CDT [23] was included in the patient-directed
instrument for the efficient assessment of cognitive, in
particular executive, function. The CDT presents patients
with a predrawn circle (10 cm diameter) and instructs
them to ‘Please draw a clock with all the numbers and
hands’ (no specific time or time limit specified). Once finished, patients are asked to ‘Write down in numbers the
time shown on the clock you have just drawn, as it would
appear on a timetable or TV guide.’ The following scoring
criteria were used [26], each requiring a yes/no decision:
CDT-1. Are exactly 12 numbers present?
CDT-2. Is the number 12 correctly placed?
CDT-3. Are there two distinguishable hands (length or
thickness)?
CDT-4. Does the time drawn correspond to the time
written in numbers (±5 minutes)?
In addition, the following GP judgment of overall CDT
accuracy was included:
CDT-5. Was the clock, including ‘time in numbers’,
perfect?
Informant-directed instrument

BrainCheck development
We describe the development of the BrainCheck instrument, followed by the feasibility and validation studies.
Methods

BrainCheck is composed of patient-directed and informantdirected components.
Patient-directed instrument

A Swiss dementia task force, strengthened by an international advisory board (see Acknowledgements), was
charged with developing a very brief (that is, applied in
a few minutes) patient-directed instrument sensitive to
subtle cognitive decline. The task force created the following yes/no questions about subjective memory performance (Q1 to Q3; cf. [37]) and depressive symptoms (Q4
and Q5 [38]):

The very short and validated seven-item version of the
IQCODE was selected as the informant-directed instrument [33]. Briefly, this tool requires informants to rate patients’ current cognitive abilities compared with 2 years
earlier. Judgments are rated on a five-point scale from
‘much improved’ (1) to ‘much worse’ (5), with (3) representing ‘no change’. Informants are typically provided with
the instructions and questions, and fill out the questionnaire on their own. The seven-item IQCODE includes the
following items:
1. Remembering things about family and friends; for
example, occupations, birthdays, addresses.
2. Remembering things that have happened recently.
3. Recalling conversations a few days later.
4. Remembering what day and month it is.
5. Remembering where to find things that have been
put in a different place from usual.
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6. Learning new things in general.
7. Handling financial matters; for example, pension,
dealing with the bank.
The total score of the seven-item IQCODE is the
mean of all items. A maximum of two missing answers
was allowed, in which case the mean of the remaining
items was used as the total score. This procedure was
adopted to increase the generalizability of the present
findings to the general practice setting, where informants
do not always provide complete questionnaire data.

Feasibility study
Following the construction of the patient-directed tool, a
feasibility study was performed to acquire GPs' judgments
on the feasibility and acceptability of the patient-directed
tool; that is, the instrument which the GP administers.
The patient-directed data collected here were not the
focus of this feasibility study and were not analyzed to
ascertain the validity of BrainCheck (see Validation
study). However, inter-rater reliability of CDT scoring
between GPs and expert memory clinic raters was calculated to determine the quality of the CDT scoring
instructions.
The ethics committees at each recruiting site approved the study (Ethikkommission beider Basel; Comité
d’Ethique Réhabilitation et Gériatrie – Psychiatrie, Hopitaux
Universitaires de Genève; Kantonale Ethikkommission
Bern; Commission d’Ethique de la Recherche Clinique,
Lausanne; Ethikkommission des Kantons St. Gallen;
Ethikkommission der beiden Stadtspitäler Triemli und
Waid, Zurich), and all participants provided informed
consent.
Methods
Participants

Fifty-two GPs from the Basel and Lausanne regions of
Switzerland agreed to assess between one and five consecutive patients fulfilling the following inclusion criteria:
suspected cognitive problems (that is, reported by patient
or informant or suspected by the GP), age ≥50 years, education ≥7 years, and fluent native speakers of German or
French. Patients with severe auditory or visual impairments who could not complete the patient-directed instrument were excluded. In total, 184 patients were tested
(60% women) with a mean age (± standard deviation) of
77.3 ± 9.1 years and a mean education of 11.5 ± 2.9 years.
Procedure

GPs administered the patient-directed tool according to
a clinical record form. Following every administration of
the patient-directed tool, GPs completed a questionnaire
on the feasibility and acceptability of the patient-directed
tool administration including judgments of wording and
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format, and patient's acceptance and understanding of the
test. Questions were rated on a five-point scale: ‘not at all’
(1), ‘a little’ (2), ‘moderately’ (3), ‘quite a bit’ (4), ‘extremely’
(5). GPs were remunerated 50 CHF for each completed
patient-directed tool questionnaire. Finally, GPs were
invited to additionally provide their global feedback on
the feasibility and acceptability of the patient-directed
tool overall on a five-point scale: ‘strongly disagree’ (1),
‘disagree’ (2), ‘neither agree nor disagree’ (3), ‘agree’ (4),
‘strongly agree’ (5).
Statistical analyses

GPs’ judgments on the feasibility and acceptability of the
patient-directed instrument were summarized descriptively.
The IRRs of CDT scoring between the GPs and expert
memory clinic raters were assessed in exploratory analyses.
Results

Fifty-two GPs administered the patient-directed tool to
184 patients in response to memory complaints by the
patient (65.8%) and/or by the informant (41.3%) and/or
based on the GP’s suspicion of cognitive problems
(42.9%). Each of these GPs rated the feasibility and
acceptability of the instrument following every test
administration.
These GPs judged the patient-directed questions to be
well accepted (4.63 ± 0.73) (mean ± standard deviation
based on the ratings ‘not at all’ (1), ‘a little’ (2), ‘moderately’ (3), ‘quite a bit’ (4), ‘extremely’ (5)) and understood
(4.41 ± 0.83) by the patients, and the CDT to be acceptable to patients (4.57 ± 0.74).
Forty-nine of the 52 GPs additionally provided global
feedback on the tool. They were satisfied with the
patient-directed instrument (3.94 ± 0.83) (rated ‘strongly
disagree’ (1), ‘disagree’ (2), ‘neither agree nor disagree’
(3), ‘agree’ (4), ‘strongly agree’ (5)). They considered the
tool to be helpful (3.80 ± 0.91), with clearly worded
questions (4.59 ± 0.67), in a format suited to the answers
patients provide (4.25 ± 0.76) and economically suited to
the healthcare system (4.41 ± 0.91). Of these physicians,
81.6% stated that they would use the tool if it was shown
to be reliable and valid (4.02 ± 1.16).
The CDT scoring IRR between the GPs and expert
raters in the feasibility study was κ = 0.50 to 0.69 for the
five CDT criteria (all P >0.0001), indicating moderate
agreement (CDT-1, κ = 0.69; CDT-2, κ = 0.50; CDT-3,
κ = 0.59; CDT-4, κ = 0.53; CDT-5, κ = 0.50). Based on
these results and verbal feedback from GPs in the
feasibility study, refined CDT scoring instructions were
created for the final version of BrainCheck. These revised
CDT scoring instructions included a list of perfect clock
criteria and additional guidance on test administration
and scoring for GPs.
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Validation study
Methods

The validation study aimed to determine the optimal
score criteria for the patient-directed instrument alone
(for patients with no informant) and the combined
BrainCheck instrument, and their corresponding CCRs
for cognitively healthy participants versus patients with
cognitive symptoms. Ethics committees at all study
sites (see Feasibility study) approved this study, and all
participants provided informed consent.
Participants

All patients who participated in the validation study had
been referred by their GPs to the memory clinics in Basel,
Geneva, Berne, Lausanne, St. Gallen and Zurich. This patient sample was independent from patients who participated in the feasibility study. All patient-directed data for
the validation study were then collected at the respective
memory clinic. All patients received a comprehensive dementia work-up at the participating site that included
comprehensive neuropsychological testing, an interview
with the informant, an internal medical and neurological
examination, psychopathological status and magnetic resonance brain imaging followed by an interdisciplinary
diagnosis conference. All diagnosing clinicians were blind
to patients’ BrainCheck results (the STARD initiative [39]).
MCI was diagnosed according to Winblad and colleagues’
criteria [40]: deficits (score <–1.28 of demographicallyadjusted z score) in one or more cognitive domain (that is,
attention, executive functioning, memory, language, visuospatial functioning, praxia and gnosis) that represent a
decline from an earlier level of cognitive functioning, but
which were not severe enough to fulfill Diagnostic and
Statistical Manual of Mental Disorders, 4th edition
(DSM-IV) criteria for dementia (that is, intact activities
of daily living as reported by next of kin). Dementia
and major depression were diagnosed according to the
DSM-IV criteria. The inclusion criteria for patients were:
complete results from all aforementioned examinations;
diagnoses of MCI [40], dementia (DSM-IV [41]) or major
depression (DSM-IV [41]); age ≥50 years; MMSE [17]
score ≥20/30; a minimum 7 years of education; and fluent
German or French language proficiency. The exclusion
criterion was the existence of sensory deficits that prohibited administration of BrainCheck.
Patient-directed data were gathered from 126 healthy
older participants of an ongoing longitudinal study at
the Memory Clinic in Basel; that is, the Basel Study on
the Elderly [36,42]. These individuals had been examined
with comprehensive neuropsychological testing and a
thorough medical questionnaire. All individuals who
fulfilled the following inclusion criteria were included
in the present analyses: cognitively, neurologically and
psychiatrically healthy; no high fever lasting longer
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than 1 week within the last week; no chronic pain; no
full anesthesia within the last 3 months; fluent German
language proficiency; and comparable age and education
levels with the patient sample (see Table 1, entire sample).
Seven-item IQCODE data were available from native
German-speaking subgroups of 70 normal control participants and 115 patients. IQCODE data for two AD patients
were excluded because of three missing items, resulting in
113 patients and 70 controls with comparable age and
education levels (see Table 1, BrainCheck subsample).
Procedure

At each memory clinic, the patient-directed instrument
was administered prior to the clinical neuropsychological
battery by trained clinicians who neither conducted the
clinical neuropsychological examination nor took part in
any interdisciplinary diagnosis conference. Administration
was standardized between memory clinics and conducted
according to the Swiss consensus guidelines [43]. The 16item German IQCODE was administered to informants in
the BrainCheck subsample according to standardized procedures [44], and data from the seven-item form (that is,
mean score [33]) were used in the present analyses.
Statistical analyses

The IRRs of CDT scoring between clinicians at the six
memory clinics and expert raters at the Basel memory
clinic were assessed in exploratory analyses.
For the following analyses, please note that the Memory
Clinic diagnosis of healthy control or patient represented
the criterion or gold standard against which the BrainCheck
data were evaluated.
A classification and regression tree (CART) analysis was
conducted to separate healthy controls from patients
based on the patient-directed data. In its first step, CART
identifies that variable which best discriminates between
two groups, here between patients and control participants. If this variable is categorical, each value produces a
branch of a tree. For each branch, the variable that best
discriminates the subset of participants on this branch
is determined, generating additional branches (for categorical variables), and so on. This process proceeds until improvements in fit fall below an a priori determined
complexity parameter of 1%. The resulting decision rule
proved to be stable in 10,000 bootstrap samples. Both the
CART and bootstrapping analyses were performed in R
software [45] using the R-package rpart. The resulting
algorithm generates a case-finding result of either further
evaluation (based on the probability that score X belongs
to the present Memory Clinic patient distribution) or
watchful waiting (based on the probability that score X
belongs to the present healthy control distribution) based
on the patient-directed instrument data alone.
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Table 1 Demographic characteristics of healthy individuals and patients in the validation study
Cognitively impaired groups
NC

Mild cognitive impairment

P value, NC vs. patients
Dementia

Major depression

Entire sample
n

126

80

185

23

Female

50 (40)

44 (55)

99 (54)

12 (52)

0.008a

Age (years)

75.2 ± 8.8

74.9 ± 8.1

78.5 ± 6.5

67.4 ± 9.6

n.s.b

Education (years)

12.5 ± 2.7

12.2 ± 2.5

11.9 ± 2.7

12.4 ± 2.7

n.s.b

MMSE

28.9 ± 1.2

27.1 ± 2.2

24.2 ± 2.5

27.9 ± 1.8

0.001b

BrainCheck subsample
n

70

21

86

6

Female

20 (29)

12 (57)

44 (51)

4 (67)

0.001a

Age (years)

77.2 ± 8.9

75.3 ± 7.5

78.4 ± 6.3

68.2 ± 11.4

n.s.b

Education (years)

12.5 ± 2.9

11.6 ± 2.1

11.7 ± 2.6

11.2 ± 1.9

n.s.b

MMSE

28.6 ± 1.2

27.5 ± 1.8

24.4 ± 2.5

27.0 ± 1.9

0.001b
a

Data presented as n (%) or mean ± standard deviation. MMSE, Mini-Mental Status Examination; NC, healthy individuals. Chi-square test. bt test.

We attempted to model the combined patient-directed
and informant-directed data using two independent
approaches: traditional logistic regression and the CART
approach described above. Both approaches failed to adequately model the combined data, most probably because
of higher-order interactions in the data associated with
highly parameterized models. A decision algorithm was
therefore developed by generating a contingency table of
the patient-directed predictor variables identified by the
CART analysis and the group variable (healthy participant
vs. patient). Homogeneous subgroups consisting of either
a high or a low proportion of patients were identified,
corresponding to a preliminary classification. This preliminary classification was extended to include informant
data from the seven-item IQCODE by determining separate optimal seven-item IQCODE mean cutoff scores for
each homogeneous subgroup via receiver operating characteristic (curve) analyses modeling optimal CCRs. The
ensuing decision rules were evaluated in 10,000 bootstrap
replicates [46] to estimate the variability of their sensitivities and specificities.
Results

CDT scores between memory clinic clinicians who regularly perform CDTs and the expert raters were comparable (IRR κ = 0.69 to 0.90; P >0.0001) (CDT-1, κ = 0.90;
CDT-2, κ = 0.85; CDT-3, κ = 0.69; CDT-4, κ = 0.78;
CDT-5, κ = 0.75).
A CART analysis was applied to the five questions (Q1
to Q5) and five CDT scoring criteria (CDT1 to CDT5)
of the patient-directed tool to derive an algorithm that
classified the maximum proportion of healthy participants
into the watchful waiting group and the maximum proportion of patients into the further examination group.

Individual item scores, as opposed to mean scores on
Q1 to Q5 and CDT, were analyzed to determine which
individual items contributed best to diagnostic discriminability. This procedure enabled us to drop inferior items,
thereby maximizing BrainCheck’s efficiency and diagnostic
accuracy.
The CART selected four questions (Q1 to Q3, Q5) and
two CDT scoring criteria (CDT-3, CDT-5) in the final
model. The top of the classification tree is occupied by
CDT-5 (perfect CDT), reflecting the largest weight in
discriminating healthy individuals from patients. A middle level of the classification tree was occupied by the
subjective questions on memory functioning (Q1 to Q3)
and CDT-3 (‘two distinguishable clock hands?’). A final
level of the tree was occupied by Q5 on depressed mood
(‘little interest or pleasure in doing things?’). Since Q5
added an additional level of complexity to the classification algorithm, CCRs were calculated for classification
algorithms with and without Q5 to determine whether
classification complexity could be reduced without sacrificing CCR. These analyses revealed comparable CCRs
with and without Q5 (difference: 1.3%); Q5 was therefore
eliminated. The final algorithm included the three
memory-related questions and two CDT items (see
Figure 1). The application of this algorithm to the entire
sample resulted in a high sensitivity (83.0%) and specificity
(79.4%), with an overall CCR of 81.2%.
The combined patient-directed and informant-directed
data were analyzed next (see Methods). The mean
seven-item IQCODE score was used, whereby one
missing item (17 patients, eight control participants)
or maximally two missing items (three patients, zero
control participants) were allowed (percentage of complete
datasets: 83% for patients, 89% for control participants). A
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Figure 1 Decision algorithm for the patient-directed tool. Sensitivity = 83.0%, specificity = 79.4%, correct classification rate = 81.2%.

six-way contingency table with the five patient-directed
variables identified by the CART analysis and the group
variable (healthy participant vs. patient) demonstrated that
the CDT-3 variable had no effect on the categorization
of the BrainCheck sample into healthy individuals versus patients. The CDT-3 variable was therefore removed
from the equation, and a second, five-way contingency
table was generated with the four remaining patientdirected variables and the group variable. This contingency
table revealed four homogeneous subgroups, corresponding
to a preliminary classification. Receiver operating characteristic (curve) analyses for each of these homogeneous
subgroups determined the IQCODE cutoff score (IQCODE_cut) that optimally categorized individuals. Thus, depending on the results of the patient-directed questions,
different seven-item IQCODE cutoff scores were used to
determine whether watchful waiting or further evaluation
was indicated, where values exceeding the cutoff score
indicate further evaluation (see Figure 2). Logically,
further evaluation would be indicated when scores on
both the patient-directed and informant-directed instruments would be deficient. However, this situation never
occurred in the present sample. We therefore added
this rule based on the aforementioned logic. The final
BrainCheck decision rules are thus as follows:
1. If patient-directed instrument = not normal and
IQCODE = not normal (that is, IQCODE mean
≥3.29), then BrainCheck = ‘further evaluation
indicated’.
2. If Q1 = no & Q2 = yes, then use IQCODE_cut = 3.07.
3. If Q1 = no & Q2 = no, then use IQCODE_cut = 3.50.
4. If Q1 = yes & Q2 = no & Q3 = no & C5 = yes, then
use IQCODE_cut = 3.31.

5. If Q1 = yes & not (Q2 = no & Q3 = no & C5 = yes),
then ‘further evaluation indicated’.
The application of these rules to the BrainCheck sample
resulted in a sensitivity of 97.3%, a specificity of 81.4%,
and a CCR of 89.35%. The classification performance
following 10,000 bootstrap replicates resulted in a mean
sensitivity of 97.4% (quartile range: 96.4 to 98.3%), a
mean specificity of 81.6% (quartile range: 78.4 to 84.6%)
and a CCR of 89.4% (see Table 2).

Discussion
The present study developed and validated BrainCheck as
a new, very short (that is about 3-minute) case-finding
tool for cognitive disturbances combining direct cognitive
testing, patients’ subjective impressions of their cognitive
functioning and informant information. The feasibility
study showed that GPs judged the administration of the
patient-directed instrument to be feasible (that is, time
efficient) and acceptable. The BrainCheck’s CCR reached
nearly 90% in the validation study. The items with the
greatest discriminatory power were questions on subjective (patient) and observed (informant) memory and
executive functioning and the results of cognitive testing
(that is, CDT). We therefore recommend the BrainCheck
as a case-finding tool, because it meets the challenge of
combining patient-directed cognitive testing, informant
information on patient functioning and patient information on subjective cognitive impairments [6] and provides
a high CCR. Because we realize that informants may not
always be available to provide information on patients, we
additionally determined the optimal scoring criteria and
diagnostic accuracy of the patient-directed instrument
alone. These analyses were performed on the largest
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Figure 2 Patient-directed and informant-directed case-finding (BrainCheck) decision algorithm. Sensitivity = 97.4%, specificity =81.6%,
correct classification rate = 89.4%. IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly.

dataset at our disposal in order to provide GPs with
the most robust and reliable findings. These analyses
revealed that the patient-directed instrument data
correctly classified 81% of the BrainCheck validation
sample, suggesting that it can be administered on its
own when no informant is available. Critically, the patients
in both validation samples were very mildly impaired (that
is, MMSE = 25.3 ± 2.8, entire sample; MMSE = 25.1 ± 2.6,
BrainCheck subsample), suggesting that this case-finding
tool can detect subtle cognitive impairments in a primary
care setting.
Cordell and colleagues recommended combining patientdirected and informant-directed case-finding questions
at older individuals’ annual wellness visits when signs
or symptoms of cognitive dysfunction are present [6].
Moreover, the new research diagnostic criteria for MCI
recommend querying informants about patients’ cognitive
functioning and the extent to which patients’ cognitive
functioning has declined [47], and research criteria for

probable AD recommend the acquisition of informant
information on patients’ cognitive functioning [48]. Informant information is critical as family members may
be more competent in judging changes in patients’ cognitive functioning in syndromes associated with an early lack
of awareness; for example, AD [30]. Moreover, informantbased case-finding tools are obviously less confrontational
for patients than direct cognitive testing.
The CDT was adopted because it is very brief and easy
to administer and has acceptable sensitivity and specificity
in differentiating healthy participants from those with
cognitive impairments [14]. However, IRR analyses showed
poor correspondence between the GPs and expert raters, in
line with previous findings [49]. In response to this finding,
we developed detailed scoring criteria for use in the GP setting. Two CDT variables – whether two distinguishable
hands are present and whether the clock is perfect – were
among the best discriminators between healthy participants
and patients based on patient-directed data alone, whereas

Table 2 Diagnostic discriminability of the individual and combined (BrainCheck) patient-directed and informantdirected screening instruments in the BrainCheck subsample
Patient-directed instrument

Sensitivity (%)

Specificity (%)

CCR (%)

85.8

74.3

79.9

Informant-directed instrument

81.4

75.7

78.6

BrainCheck

97.4

81.6

89.4

CCR, correct classification rate.
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only the whether the clock is perfect variable survived
in the BrainCheck algorithm. Similarly, Scanlan and
colleagues recommended that untrained examiners use
the rating normal CDT versus abnormal CDT for the
classification of healthy versus demented individuals
[50] (see also [13]). We note that 32% of healthy participants in the patient-directed sample drew imperfect
clocks; it is therefore advisable to combine the CDT with
other case-finding instruments for cognitive impairment.
Case-finding tools similar to the patient-directed and
informant-directed components of BrainCheck exist (see
Introduction and [4]), although to our knowledge no
published tool combines the three sources of information
deemed critical for optimal case-finding (that is, cognitive
testing of patient, informant information, patients’ subjective impressions of their cognitive functioning) into a
single, very short tool [6]. Perhaps the most similar tool
in content and length is the GPCOG, which combines
patient-directed cognitive testing and six informant
questions [28]. In a validation study, Brodaty and colleagues
studied 283 individuals from the community who complained of memory impairment [28]. The GPCOG was
administered by local GPs, and the diagnostic gold
standard was defined as memory clinic diagnoses. In
this sample, the patient-directed GPCOG’s sensitivity
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and specificity were 82% and 70%, compared with 89%
sensitivity and 66% specificity for the informant-directed
GPCOG. The patterns of sensitivity and specificity in the
GPCOG and BrainCheck patient-directed and informantdirected tools were thus similar, with greater sensitivity
than specificity and overall comparable diagnostic accuracies across the two sources of data. The higher diagnostic
accuracy for BrainCheck compared with GPCOG most
probably originates from the nature of the present sample:
memory clinic patients are more likely to have a positive
diagnosis, and the healthy individuals participating in
research studies are more likely to have a negative
diagnosis compared with community-based residents.
As the MMSE was used to select patients for the
present validation study, a direct comparison of MMSE
and BrainCheck sensitivity and specificity rates in the
present sample is not warranted. Both the GPCOG and
BrainCheck are thus brief, encompass multiple domains
and demonstrate good diagnostic accuracy. BrainCheck’s,
but not GPCOG’s, demonstrably superior diagnostic
accuracy compared with the MMSE may be accounted
for by the greater variability in MMSE administration
methods across different GP practices in Brodaty and
colleagues’ study [28] and BrainCheck’s inclusion of information on the patient’s subjective cognitive functioning.

Figure 3 Simplified, paper-and-pencil flowchart version of BrainCheck modified for optimally efficient administration. In contrast to the
decision algorithm (cf. Figures 1, 2), this simplified version requires the IQCODE sum. This version can therefore only be used when complete
IQCODE data are available (that is, no missing data). IQCODE, Informant Questionnaire on Cognitive Decline in the Elderly.
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There are three caveats to the present study. First, as
noted above, the BrainCheck CCR is potentially artificially
inflated by an inestimable magnitude since patients referred to a memory clinic more probably represent a
subset of primary care patients with more cognitive
impairment, and optimally healthy participants from
the validation study are those that are less likely to be
screened by GPs. Second, as with any validation study,
we note that external validation, particularly in the GP
setting, is required to confirm the performance levels
of the patient-directed instrument alone and BrainCheck.
We note that correct classification rates from studies in
the GP setting are generally lower than those obtained
from memory clinic samples. Finally, we note that our
validation study sample included too few patients with
depression to reliably test the validity of case-finding
questions about this disorder.

Conclusions
There are several advantages to the new BrainCheck casefinding tool. First, there is no formal episodic memory
task, which is time consuming and frequently frustrates
patients and possibly GPs. Second, the patient-directed instrument can be administered in a very short time (that is,
circa 3 minutes). Third, the seven-item IQCODE may be
administered by a nurse, the physician's assistant or other
trained professionals, saving the GP additional time. We
provide decision algorithms that enable GPs to determine
whether further evaluation or watchful waiting is indicated;
that is, repeated screening in 6 to 12 months. When such a
patient scores within the range of the present Memory
Clinic patient sample, then the algorithm recommends further evaluation since an underlying syndrome is more
probable. If the GP’s patient with suspected cognitive symptoms scores within the range of the present control sample,
then the algorithm recommends watchful waiting; that is,
the longitudinal observation of suspected cognitive symptoms. Lastly, while the BrainCheck decision algorithm is
complex, we developed an easy-to-use App for the iPhone
and iPad (Android app under development) for GPs and
other healthcare service providers for a one-time nominal
charge that automatically calculates the BrainCheck results.
We also offer a paper-and-pencil version of the BrainCheck
free of charge. The paper-and-pencil version has been
modified to be optimally efficient, as it includes only those
questions necessary to derive a decision (see Figure 3). In
summary, BrainCheck meets criteria for an efficient and
effective routine case-finding tool for primary care patients
with suspected cognitive symptoms: it is brief, simple to
use, sensitive and specific.
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